Company Overview - Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biotechnology company focused on developing treatments for prostate and kidney cancer [2] - The company's prostate cancer therapy candidate TLX591 is currently in a phase three study called ProstACT, which aims to enroll approximately 490 patients [2] Recent Developments - On December 8th, Telix Pharmaceuticals announced that it had dosed the first patient in part two of the ProstACT study [2] - In September, the company received Medicare and Medicaid's Transitional Pass-Through payment status for its prostate cancer imaging agent Gozellix, allowing hospitals to receive separate reimbursement for its use [3] Financial Performance - In the third quarter, Telix Pharmaceuticals reported $206 million in revenue, reflecting a 53% annual growth [3] - The company increased its fiscal 2025 revenue guidance to $820 million from $800 million, with revenue from imaging products like Gozellix contributing significantly to sales [3]
Telix Pharma (TLX) Makes Progress With New Study